Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GLPG5101 (19CP02) CAR T cells in relapsed/refractory B‑cell non-Hodgkin lymphoma
2022-502661-23-00Phase 2Completed
- Sponsor
- Lakefront Biotherapeutics
- Start
- Dec 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of GLPG5101 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 5 more, sponsored by Lakefront Biotherapeutics. Primary endpoints: Incidence of (serious) adverse events and dose-limiting toxicities and Objective response (OR) per Lugano Classification or IPCG criteria. Started Dec 2022; status: completed.
02
Drugs
GLPG5101
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-502661-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502661-23-00.